Triftazin-Darnytsia (trifluoperazine) solution for injections 2 mg/ml. 1ml. vials №10

Description

Triftazin-Darnytsia (trifluoperazine) solution for injections 2 mg/ml. 1ml. vials №10

Composition

active substance: trifluoperazine;

1 ml of solution contains trifluoperazine hydrochloride 2 mg;

Excipients: sodium citrate, water for injections.

Dosage form

Solution for injection.

Main physical and chemical properties: clear colorless or slightly yellowish liquid.

Pharmacotherapeutic group

Antipsychotics. Piperazine derivatives of phenothiazine.
ATX code N05A B06.

Pharmacological properties

It is an antipsychotic (neuroleptic). It has a pronounced antipsychotic, antiemetic effect. Also has alpha-adrenolytic, mild sedative and anticholinergic effects. It has a long-term and pronounced effect on productive mental symptoms (delirium, hallucinations). May cause extrapyramidal disorders.

Indications

Triftazin-Darnytsia is used for schizophrenia and other mental illnesses that occur with hallucinations, delirium, and psychomotor agitation.

Contraindications

Triftazin-Darnytsia is not used:

• if you are allergic to trifluoperazine, other components of the drug;
• with suppression of the function of the central nervous system, coma;
• with TBI;
• with pathology of the kidneys, liver, hematopoietic organs with a violation of their functions;
• with progressive systemic diseases of the spinal cord or brain;
• with peptic ulcer of the duodenum, stomach in the acute phase;
• with decompensated heart failure;
• with severe arterial hypotension;
• for diseases accompanied by the risk of thromboembolic complications;
• with angle-closure glaucoma;
• with prostatic hyperplasia;
• with myxedema;
• during pregnancy / lactation.

Triftazin-Darnytsia is used with caution:

• in the treatment of elderly patients;
• with vomiting (may mask vomiting associated with drug intoxication);
• with alcohol intoxication;
• with Reye’s syndrome;
• with cachexia;
• with breast cancer;
• with Parkinson’s disease;
• with urinary retention;
• with chronic diseases of the respiratory organs;
• with epileptic seizures.

Application during pregnancy and lactation

Contraindicated.

Method of administration and dosage

The drug Triftazin-Darnytsia is used intramuscularly.
The standard dose for the treatment of anxiety conditions is 1 mg 2 times / day; psychotic disorders – 2-5 mg 2 times / day. To obtain the optimal effect, the dose is gradually increased to 15-20 mg / day. The maximum is 40 mg / day.
For elderly patients, the dose is reduced.

Overdose

Symptoms: areflexia / hyperreflexia, cardiotoxic effects (heart failure, arrhythmia, drop in blood pressure, tachycardia, shock, ventricular fibrillation, changes in the QRS complex, cardiac arrest), blurred vision, neurotoxic effects (agitation, confusion, disorientation, convulsions , stupor, coma), dry mouth, mydriasis, hyperpyrexia / hypothermia, muscle stiffness, pulmonary edema, vomiting, respiratory depression.
Symptomatic treatment is carried out. Control of the function of the cardiovascular system, respiration, central nervous system, thermometry, psychiatric consultation.

Side effects:

• Neurological disorders: drowsiness, insomnia, dizziness, mental indifference, extrapyramidal disorders (dyskinesia, akinetic phenomena, tremor, akathisia, hyperkinesis, autonomic disorders), convulsions, neuroleptic malignant syndrome.
• Ophthalmic disorders: paresis of accommodation, retinopathy, opacity of the cornea or lens.
• Genitourinary disorders: urinary retention, frigidity, decreased potency, decreased libido, priapism, ejaculation disorders, oliguria.
• Endocrine disorders: hypo / hyperglycemia, amenorrhea, glucosuria, hyperprolactinemia, galactorrhea, dysmenorrhea, breast swelling, gynecomastia, mastalgia, weight gain.
• Digestive disorders: dry mouth, constipation, decreased appetite, bulimia, vomiting, gastralgia, diarrhea, cholestatic jaundice.
• Changes in laboratory parameters: thrombocytopenia, increased blood clotting, lymph / leukopenia, anemia, agranulocytosis, eosinophilia, pancytopenia, false positive pregnancy test.
• Cardiovascular disorders: tachycardia, orthostatic hypotension, arrhythmia, lengthening of the Q – T interval, inversion or decrease in the T wave. Allergic reactions: urticaria, skin rash, angioedema.
• Others: melanosis, pigmentation of the conjunctiva, skin, discoloration of the cornea and sclera, decreased tolerance to high temperatures (heatstroke may develop).